ArticleAntimicrobial agents and chemotherapy1994
Pharmacokinetics, toxicity, and efficacy of liposomal capreomycin in disseminated Mycobacterium avium beige mouse model.
Article in Antimicrobial agents and chemotherapy, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 33 citations in OpenAlex.
- Meeting Contemporary Challenges: Development of Nanomaterials for Veterinary Medicine.Pharmaceutics · 2023Review
- Structure-Activity Relationships of Wollamide Cyclic Hexapeptides with Activity against Drug-Resistant and IntracellularAntimicrobial agents and chemotherapy · 2019Article
- Theranostics Aspects of Various Nanoparticles in Veterinary Medicine.International journal of molecular sciences · 2018Review
- Mouse model for efficacy testing of antituberculosis agents via intrapulmonary delivery.Antimicrobial agents and chemotherapy · 2012Article
- Pharmacokinetics of sequential doses of capreomycin powder for inhalation in guinea pigs.Antimicrobial agents and chemotherapy · 2012Article
- A physiologically based pharmacokinetic model for capreomycin.Antimicrobial agents and chemotherapy · 2012Article
- Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model.Antimicrobial agents and chemotherapy · 2007Article
- Unilamellar vesicles as potential capreomycin sulfate carriers: preparation and physicochemical characterization.AAPS PharmSciTech · 2004Article
- Relationship of pharmacokinetically-calculated volumes of distribution to the physiologic distribution of liposomal drugs in tissues: implications for the characterization of liposomal formulations.Pharmaceutical research · 2001Article
- Therapeutic efficacy of liposomal rifabutin in a Mycobacterium avium model of infection.Antimicrobial agents and chemotherapy · 2000Article
- Effective treatment of acute and chronic murine tuberculosis with liposome-encapsulated clofazimine.Antimicrobial agents and chemotherapy · 1999Article
- Therapeutic efficacy of liposomal clofazimine against Mycobacterium avium complex in mice depends on size of initial inoculum and duration of infection.Antimicrobial agents and chemotherapy · 1997Article
- Liposome encapsulation of clofazimine reduces toxicity in vitro and in vivo and improves therapeutic efficacy in the beige mouse model of disseminated Mycobacterium avium-M. intracellulare complex infection.Antimicrobial agents and chemotherapy · 1996Article
- Formulation and efficacy of liposome-encapsulated antibiotics for therapy of intracellular Mycobacterium avium infection.Antimicrobial agents and chemotherapy · 1995Article
- Beige mouse model for Mycobacterium avium complex disease.Antimicrobial agents and chemotherapy · 1995Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Capreomycin was incorporated into multilamellar vesicles of pure dipalmitoylphosphatidylcholine. The pharmacokinetics and nephrotoxicity of capreomycin in the free and liposomal forms were studied in normal mice. The efficacies of the two forms were evaluated by using the Mycobacterium avium complex beige mouse model. Approximately 10(7) viable M. avium cells were injected intravenously. Seven days later, treatment with either liposomal or free capreomycin at 60 or 120 mg/kg of body weight was administered daily for 5 days. Mice were sacrificed 5 days after the end of treatment, and the viable bacteria in liver, spleen, lungs, and blood were counted. After 5 days of treatment with dosages of 60 or 120 mg/kg/day, the level of blood urea nitrogen increased in the group treated with free capreomycin but not in the group treated with liposomal capreomycin. After intravenous injection of 120 mg/kg, liposomes enhanced the diffusion of capreomycin in the spleen, lungs, and kidneys and increased the half-life in serum. The 120-mg/kg dose of liposomal capreomycin significantly reduced the number of viable mycobacteria in the liver, spleen, and blood compared with those in the controls. Although these results are promising, further studies are needed to assess the efficacy of liposomal capreomycin for the treatment of M. avium complex infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.